Efficacy against acute exacerbations of schizophrenia looks strong in top-line phase III data from the four-week Enlighten-1 trial with Alkermes plc's ALKS-3831, but the world won't know until next year about the weight gain and metabolic aspects investigated by a six-month experiment called Enlighten-2.